Canopy Growth (CGC) Long-Term Investments (2018 - 2026)
Canopy Growth (CGC) posted Long-Term Investments of $78.8 million for Q1 2026, down 29.21% sequentially from $111.3 million in Q4 2025, and down 37.21% YoY from $125.4 million in Q1 2025.
Canopy Growth (CGC) Long-Term Investments (2018 - 2026) Analysis & Trends
Canopy Growth has reported Long-Term Investments for 9 years, with the latest figure at $78.8 million in Q1 2026.
- Quarterly Long-Term Investments fell 37.21% year-over-year to $78.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.8 million (down 37.21% YoY) and the FY2026 annual result came in at $78.8 million, down 37.21% from the prior year.
- Long-Term Investments fell to $78.8 million in Q1 2026 per CGC's latest filing, from $111.3 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $324.8 million in Q1 2024 and troughed at $24.2 million in Q4 2023.
- A 5-year average of $91.7 million and a median of $76.6 million in 2026 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2024 and 2025: Long-Term Investments surged 692.78% in 2024, then tumbled 61.38% in 2025.
- Over 5 years, Long-Term Investments stood at $27.3 million in 2022, then retreated by 11.07% to $24.2 million in 2023, then soared by 47.17% to $35.7 million in 2024, then soared by 211.87% to $111.3 million in 2025, then decreased by 29.21% to $78.8 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $78.8 million, $111.3 million, and $137.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 92.58 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 63.23 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 1.14 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 60.00 Mn |
| 10 | Canopy Growth | 445.49 Mn | 198.48 Mn | 16.08 Mn | 90.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.70 Mn |
| Mar 31, 2026 | 78.76 Mn |
| Dec 31, 2025 | 111.26 Mn |
| Sep 30, 2025 | 137.38 Mn |
| Jun 30, 2025 | 116.85 Mn |
| Mar 31, 2025 | 125.43 Mn |
| Dec 31, 2024 | 35.67 Mn |
| Sep 30, 2024 | 99.97 Mn |
| Jun 30, 2024 | 110.16 Mn |
| Mar 31, 2024 | 324.77 Mn |
| Dec 31, 2023 | 24.24 Mn |
| Sep 30, 2023 | 57.44 Mn |
| Jun 30, 2023 | 74.48 Mn |
| Mar 31, 2023 | 40.97 Mn |
| Dec 31, 2022 | 27.26 Mn |
| Sep 30, 2022 | 55.21 Mn |
| Jun 30, 2022 | 47.06 Mn |
| Mar 31, 2021 | 79,009.91 |
| Dec 31, 2020 | 13.03 Mn |
| Sep 30, 2020 | 19.26 Mn |